| Patent Number |
Title Of Patent |
Date Issued |
| 7276473 |
Methods and compositions for the treatment of pancreatitis |
October 2, 2007 |
| Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas. |
| 6897227 |
Prodrugs of proton pump inhibitors |
May 24, 2005 |
| Prodrugs of proton pump inhibitors of Formulas 1 through 4, ##STR1##where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability. |
| 6843998 |
Methods and compositions for the treatment of pancreatitis |
January 18, 2005 |
| Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas. |
| 6776990 |
Methods and compositions for the treatment of pancreatitis |
August 17, 2004 |
| Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas. |
| 6559167 |
Prodrugs of proton pump inhibitors |
May 6, 2003 |
| Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pum |
| 6274173 |
Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
August 14, 2001 |
| An oral pharmaceutical composition comprises an acid-labile irreversible proton pump inhibitor in pellet or tablet form, wherein the irreversible proton pump inhibitor is at least partly in slow-release form. On combined administration with an anti-microbially-active ingredient, the comp |
| 6271256 |
Methods for controlling gram negative bacteria in mammals with bicyclo spiroether compounds |
August 7, 2001 |
| Methods for controlling growth of gram negative bacteria, such as Helicobacter pylori, which are agents associated with disorders of the gastrointestinal tract of a mammal are described. They include administering a therapeutically effective amount of a polyether ionophore antibiotic |
| 6132768 |
Oral pharmaceutical composition with delayed release of active ingredient for reversible proton |
October 17, 2000 |
| An oral pharmaceutical composition of a reversible proton pump inhibitor in pellet or tablet form, wherein the reversible proton pump inhibitor is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced |
| 6093734 |
Prodrugs of proton pump inhibitors |
July 25, 2000 |
| Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The prodrugs of the inventio |
| 6068856 |
Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
May 30, 2000 |
| An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders ca |
| 6017950 |
Methods for controlling gram negative bacteria in mammals |
January 25, 2000 |
| Methods for controlling growth of gram negative bacteria, such as Helicobacter pylori, which are agents associated with disorders of the gastrointestinal tract of a mammal are described. They include administering a therapeutically effective amount of a polyether ionophore antibiotic |
| 5945124 |
Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
August 31, 1999 |
| An oral pharmaceutical composition of pantoprazole in pellet or tablet form, wherein the pantoprazole is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced action of rapid onset against disorders ca |
| 5942409 |
Process for identification of substances modulating ureI dependent mechanisms of Helicobacter py |
August 24, 1999 |
| The present invention provides a screening process for the identification of anti-helicobactericidal substances modulating ureI dependent mechanisms of gastric Helicobacter metabolism. Gastric Helicobacter cells are treated with a substance to be tested for modulating ureI dependent mech |
| 5183906 |
2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5H |
February 2, 1993 |
| Novel anti-inflammatory furanone compounds have the following formula ##STR1## where R.sub.1 independently is H, phenyl, C.sub.1 -C.sub.6 alkyl substituted phenyl, halogen substituted phenyl, or alkyl of 1 to 6 carbons and n is an integer having the values of 1 or 2, and where when n |
| 5075323 |
Compounds including omeprazole in the treatment of glaucoma |
December 24, 1991 |
| A method for the treatment of diseases related to an increased intraocular pressure in the eye comprising administration to a patient suffering therefrom an amount of a compound of the formula I ##STR1## or a pharmaceutically acceptable salt thereof. |
| 4839385 |
Use of manoalide and its derivatives for modifying calcium homeostasis |
June 13, 1989 |
| Compounds derived form the marine sponge Laffariella variabilis and known by the name manoalide, and its derivatives, modify calcium homeostasis. |
